How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Guérin?

Kamat, 2016, Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group, J Clin Oncol, 34, 1935, 10.1200/JCO.2015.64.4070 Babjuk, 2017, EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016, Eur Urol, 71, 447, 10.1016/j.eururo.2016.05.041 Babjuk, 2019 FDA. FDA definition of BCG-unresponsive disease. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM529600.pdf. Nieder, 2005, Management of stage T1 tumors of the bladder: International Consensus Panel, Urology, 66, 108, 10.1016/j.urology.2005.08.066 Sylvester, 2006, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials, Eur Urol, 49, 466, 10.1016/j.eururo.2005.12.031 Fernandez-Gomez, 2009, Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model, J Urol, 182, 2195, 10.1016/j.juro.2009.07.016 Fritsche, 2010, Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort, Eur Urol, 57, 300, 10.1016/j.eururo.2009.09.024 Lazica, 2014, Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center, Urol Int, 92, 131, 10.1159/000353089 Gallagher, 2017, Real-life experience’: recurrence rate at 3 years with Hexvix(®) photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC—a prospective controlled study, World J Urol, 35, 1871, 10.1007/s00345-017-2077-6 Lerner, 2009, Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer, Urol Oncol, 27, 155, 10.1016/j.urolonc.2007.11.033 Hautmann, 2009, Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1G3), World J Urol, 27, 347, 10.1007/s00345-009-0402-4 Nativ, 2009, Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin, J Urol, 182, 1313, 10.1016/j.juro.2009.06.017 Lorenzo, 2010, Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle invasive bladder cancer, Cancer, 116, 1893, 10.1002/cncr.24914 Yates, 2012, Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer, Eur Urol, 62, 1088, 10.1016/j.eururo.2012.08.055 Li, 2018, Treatment options for patients with recurrent tumors after BCG therapy. Are we ignoring the obvious?, Eur Urol, 74, 405, 10.1016/j.eururo.2018.04.012 Joudi, 2006, Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer, Urol Oncol, 24, 344, 10.1016/j.urolonc.2005.11.026 Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904 de Wit, 2018, Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): phase 2 KEYNOTE-057 trial, Ann Oncol, 29, viii303 Palou Redorta, 2006, Management of BCG “failures”, Eur Urol, 49, 779, 10.1016/j.eururo.2006.03.006 Kamat, 2018, Predicting response to intravesical bacillus Calmette-Guérin immunotherapy: are we there yet?. A systematic review, Euro Urol, 73, 738, 10.1016/j.eururo.2017.10.003 Yates, 2015, T1G3 bladder cancer and bacillus Calmette-Guérin: tell me something we don’t know, Eur Urol, 67, 74, 10.1016/j.eururo.2014.07.019 Schrier, 2004, Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy, Eur Urol, 45, 292, 10.1016/j.eururo.2003.10.006 Haas, 2016, The timing of radical cystectomy for bacillus Calmette-Guerin failure and risk factors for prognosis, J Urol, 195, 1704, 10.1016/j.juro.2016.01.087 Tilki, 2010, Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients, J Urol, 183, 1757, 10.1016/j.juro.2010.01.025 Huguet, 2005, Cystectomy in patients with high risk superficial bladder tumours who fail intravesical therapy: pre-cystectomy prostate involvement as a prognostic factor, Eur Urol, 48, 53, 10.1016/j.eururo.2005.03.021 Mmeje, 2016, Papillary recurrence of bladder cancer at first evaluation after induction bacillus Calmette-Guérin therapy: implication for clinical trial design, Eur Urol, 70, 778, 10.1016/j.eururo.2016.02.031 Boorjian, 2013, Comparative performance of comorbidity indices for estimating perioperative and 5-year all-cause mortality following radical cystectomy for bladder cancer, J Urol, 190, 55, 10.1016/j.juro.2013.01.010 Steinberg, 2000, Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group, J Urol, 163, 761, 10.1016/S0022-5347(05)67799-3 Steinberg, 2015, Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer, Bladder Cancer, 1, 65, 10.3233/BLC-150008